A case of interstitial lung disease with atorvastatin (Tahor®) and a review of the literature about these effects observed under statins;Un cas de Pneumopathie interstitielle rapporté sous atorvastatine (Tahor®): Synthèse des cas publiés sous statines

Therapie

Volumn 61, Issue 1, 2006, Pages 57-67

  Veyrac, Gwenaëlle ^a   Cellerin, Laurent ^a   Jolliet, Pascale ^a  

^a INSTITUT DE BIOLOGIE   (France)

Author keywords

Atorvastatin; Interstitial lung disease; Statins

Indexed keywords

ALPHA TOCOPHEROL; AMINOTRANSFERASE; ATORVASTATIN; BECLOMETASONE; CHLORPHENIRAMINE; CHOLESTEROL; CORTICOSTEROID; CREATINE KINASE; CYCLOSPORIN; FENOFIBRATE; FUSIDIC ACID; GEMFIBROZIL; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPRATROPIUM BROMIDE; LEVOTHYROXINE; METHYLPREDNISOLONE; OXAPROZIN; PRAVASTATIN; PSEUDOEPHEDRINE; SALBUTAMOL; SIMVASTATIN; TOCO; TRIAMCINOLONE; UNCLASSIFIED DRUG; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; CASE REPORT; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INTERSTITIAL LUNG DISEASE; LONG TERM CARE; MALE; MYALGIA; ORGAN TRANSPLANTATION; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; ARTICLE; CHEMICALLY INDUCED DISORDER; LUNG; PATHOLOGY; RHABDOMYOLYSIS; THORAX RADIOGRAPHY;

HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUNG; LUNG DISEASES, INTERSTITIAL; PYRROLES; RADIOGRAPHY, THORACIC; RHABDOMYOLYSIS;

EID: 33747063355     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2006017     Document Type: Article

References (23)

1. Raggatt LJ, Partridge NC. HMG-CoA reductase inhibitors as immunomodulators. Potential use in transplant rejection. Drugs 2002; 62: 2185-2191
2. Mach F. Statins as immunomodulators. Transpl Immunol 2002; 9: 197-200
3. Danesh FR, Anel RL, Zend L, et al. Immunomodulatory effects of HMG-CoA reductase inhibitors. Arch Immunol Ther Exp 2003; 51: 139-148
4. Begaud B, Evreux JC, Jouglard J, et al. Imputabilité des effets inattendus ou toxiques des médicaments. Therapie 1985; 40: 111-118
5. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors. Treatment and trust. Drugs 2001; 61: 197-206
6. Malhotra HS, Goa KL. Atorvastatin. An updated review of its pharmacological properties and use in dyslipidemia. Drugs 2001; 61: 1835-1881
7. Sulem P, Bagheri H, Faiso Y, et al. Atorvastatin-induced diaphragmatic muscle impairment. Ann Pharmacother 2001; 35: 1292-1293
8. e édition Tome 1. Paris: Medecine-Sciences Flammarion , 2004: 1029-1030
9. Camus Ph, Foucher P. Accidents respiratoires médicamenteux diagnostic clinique et conduite à tenir. In Flammarion Médecine Sciences 1997; 67: 751-761
10. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust NZ J Med 1995; 25: 745-746
11. De Groot REB, Willems LNA, Dijkman JH. Interstitial lung disease with pleural effusion caused by simvastin. J Inter Med 1996; 239: 361-363
12. Liebhaber MI, Wright RS, Gelberg HJ, et al. Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors. A report often cases. Chest 1999; 115: 886-889
13. Liscoet-Loheac N, Andre N, Couturaud F, et al. Une Pneumopathie iatrogénique rapportée à la prise de pravastatine. Rev Mal Respir 2001; 18: 426-428
14. Lantuejoul S, Brambilla E, Brambilla C, et al. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J 2002; 19: 577-580
15. Stoabner PE, Michot C, Ligeron C, et al. Simvastatin-induced lichen planus pemphigoides. Ann Dermatol Venereol 2003; 130: 187-190
16. Weinstein A. Drug-induced systemic lupus erythematous. Prog Clin Immunol 1980; 4: 1-21
17. Ahmad S. Lovastatin-induced lupus erythematous. Arch Intern Med 1991; 151: 1667-1668
18. Bannwarth BB, Miremont G, Papapietro PM. Lupus-like syndrome associated with simvastatin. Arch Intern Med 1992; 152: 1093 [letter]
19. Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 1821-1854
20. Bocan TM. Pleiotropic effects of HMG-CoA reductase inhibitors. Curr Opin Investig Drugs 2002; 3: 1312-1317
21. Nalbone G, Bernot D, Peiretti F, et al. Statins: maid-of-all-work in cardiovascular diseases! Arch Mal Coeur Vaiss 2003; 96: 207-213
22. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402
23. Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003; 167: 1271-1278